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Abstract
Background: Both in vitro and epidemiological studies indicate that dietary polyunsaturated fatty
acids may play a protective role against peptic ulcer in humans. Adipose tissue fatty acid
composition is thought to reflect dietary fatty acid intake. The aim of the present study is to
investigate adipose and gastric mucosa fatty acid levels in relation to gastric ulceration status.
Methods:  Fifty two adult outpatients undergoing upper gastrointestinal tract endoscopy
participated in the study. Adipose tissue samples were taken from the abdomen and buttock during
the endoscopy procedure and samples from gastric tissue were taken from a subsample of 30
subjects. The presence of Helicobacter pylori was determined using the CLO test. Capillary gas
chromatography was used for the extraction of 36 and 42 adipose tissue and gastric mucosa lipids
respectively.
Results: The monounsaturated fatty acids (MUFAs) C18:1n-12c, C16:1n-5, C16:4n-1 and the
polyunsaturated fatty acids (PUFAs) C16:3n-4, C20:3n-3, C20:4n-6, C21:5n-3 and C18:2n-9c,12t of
the gastric mucosa were present in higher proportions in ulcer negative patients. These
unsaturated fatty acids, however, each contributed less than 1% on average to total fatty acid
content. In addition, higher average levels of eicosapentaenoic acid (EPA) C20:5n-3 and
docosahexaenoic acid (DHA) C22:6n-3 were detected in abdominal and buttock samples in CLO
negative controls, compared to CLO positive controls. Adipose tissue and gastric mucosa n-6 and
trans fatty acid levels were positively linearly correlated (r = 0.37 and 0.41 for n-6 and trans fatty
acids respectively).
Conclusion: Certain minor MUFAs and PUFAs of the gastric mucosa appear to be present in
higher proportions in ulcer negative patients. Overall, the findings provide only weak evidence of
an association between the gastric mucosal fatty acids and the presence of gastric ulceration. The
higher average levels of EPA and DHA in abdominal and buttock adipose tissue in CLO negative
controls could be an indicator that dietary FAs inhibit Helicobacter pylori growth. Larger studies are
necessary to provide evidence of a biologically relevant effect.
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Background
For more than a century, peptic ulcer disease has been a
major cause of morbidity and mortality. The pathophysi-
ology of peptic ulcer disease has centered on an imbalance
between aggressive and protective factors in the stomach
[1].
Twenty five years have elapsed since Marshall and War-
ren's discovery of the link between Helicobacter pylori (H.
pylori) infection and peptic ulcer disease [2]. The clinical
outcome of H. pylori infection is most likely the result of
complex interactions between bacterial, environmental,
and host-related factors [3,4]. The prevalence of H. pylori
infection varies, has been decreasing in the last few dec-
ades in most developed countries [4]. Epidemiological
evidence suggests that the declining prevalence of peptic
ulcer disease may be partially attributable to increased
consumption of polyunsaturated fatty acids (PUFAs), a
hypothesis supported by in vitro evidence of toxicity of
such substances to H. pylori [5].
It has therefore been suggested that dietary fat plays a pro-
tective role against peptic ulcer disease. The fatty acids
(FAs) present in adipose tissue include certain fatty acids
that cannot be endogenously synthesized and are, conse-
quently, considered valid biomarkers of the dietary intake
of these FAs [6]. Since adipose tissue has a slow turnover,
it is an attractive choice for the study of long-term dietary
fatty acid intake [6]. Fatty acids that cannot be synthesized
endogenously from carbohydrates and which are consid-
ered valid biomarkers of dietary fatty acid intake are: n-3
PUFAs, such as linoleic acid (C18:2n-6), eicosapentaenoic
acid (EPA) (C20:5n-3) and docosahexaenoic acid (DHA)
(C22:6n-3), n-6 PUFAs, such as α-linoleic acid (18:3n-3),
trans FAs and odd-numbered and branched-chain FAs [7].
Monounsaturated FAs (MUFAs) and saturated FAs (SFAs)
do not reflect dietary intake patterns, with the exception
of odd-numbered SFAs [6].
It is possible that some PUFAs, especially those of the n-3
group, are able to modulate the immune responses to H.
pylori. Many studies report the effects of ingested FAs on
molecular and cellular aspects of immunity [8]. SFAs are
able to induce the activation of TLR2 and TLR4, whereas
unsaturated FAs, such as n-3, inhibit TLR-mediated signal-
ing pathways and gene expression [9,10]. In addition, any
diet-induced variation in fatty acid composition of fat
depots may influence directly the membrane organization
of immune cells and result in impaired functionality
[11,12]. In particular, dietary n-3 PUFAs alter T cell mem-
brane microdomain composition and may therefore
influence signaling complexes and modulate T cell activa-
tion in vivo [13,14].
Prostaglandins (PGs) play an important role in maintain-
ing the gastro duodenal mucosal integrity [15]. PGs stim-
ulate mucosal bicarbonate secretion, accelerate cell
proliferation, enhance mucus secretion and mucosal
blood flow, increase mucosal sulfhydryl groups and pro-
mote both lysosomal stability and the formation of
mucosal phospholipids [16-19]. Dietary linoleic acid
(C18:2n-6) is converted to arachidonic acid (C20:4n-6)
which is the main unsaturated 20-carbon fatty acid used
for the production of PGs via the cyclooxygenase path-
way. Thus, an increased intake of linoleic acid might lead
to an enhanced production of endogenous PGs.
The phospholipids of the gastric mucosa provide a hydro-
phobic lining that protects against extrinsic and intrinsic
insults. The saturation level and the chain length of the
FAs incorporated into these phospholipids influence both
the membrane hydrophobicity and permeability [20].
Although some studies have examined the gastric mucosa
in relation to H. pylori, little is known about the fatty acid
composition of the gastric mucosa in relation to gastric
ulceration. The aim of the present study is to compare the
fatty acid composition of adipose tissue and gastric
mucosa in subjects with gastric ulceration and subjects
without evidence of ulceration.
Methods
Subjects
The study was conducted between June 2000 and Novem-
ber 2004 at the Gastroenterology Outpatient clinic of the
University Hospital of Crete. Eligible patients were those
with present or past abdominal complaints, who under-
went upper gastrointestinal endoscopy screening. Patients
were excluded if they were known to have concurrent ill-
ness, were on any medication or had taken H2 receptor
antagonists, proton pump inhibitors, bismuth, antibiot-
ics, non-steroidal anti-inflammatory drugs, or corticoster-
oids within 2 months of the examination. Fifty-two
patients, all residents of the island of Crete, participated in
the study. Patient ages ranged from 21 to 89 years (mean
age 60, SD 16.9, median 64 years). The percentage of
female subjects was similar in patients with and without
gastric ulceration, being 9 out of 16 (56%) and 21 out of
36 (58%) respectively. All patients gave informed consent
before the endoscopy, the endoscopic biopsy and the col-
lection of adipose tissue samples. The study was approved
by the Ethics Committee of the Medical School of the Uni-
versity of Crete.
The collection of the abdominal and buttock subcutane-
ous tissue samples as well as that of the gastric tissue was
performed at the Department of Gastroenterology of the
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All patients provided buttock subcutaneous tissue sam-
ples and 42 provided abdominal subcutaneous tissue
samples. Gastric mucosa tissue samples were taken in a
subset of 30 patients.
Detection of gastric ulcer
The presence of gastric ulcer was determined by upper gas-
trointestinal tract endoscopy conducted in the Depart-
ment of Gastroenterology of the University Hospital of
Heraklion, Crete.
Detection of H. pylori infection
The rapid urease CLO test was used for detecting H. pylori
from gastric antral biopsy specimens. This test has been
reported to have high sensitivity and specificity [21].
Biopsy specimens were taken from twenty-five patients,
for histological examination. The histological results
matched the results from the CLO test in all cases.
Adipose tissue measures
Both abdominal and buttock subcutaneous adipose tissue
samples were collected since there are reported differences
in fatty acid content among abdominal and buttock
depots [22]. Abdominal and buttock tissue samples were
collected by aspiration, using the method described by
Beynen and Katan [23]. The particular method is known
to be rapid and safe, causing no more discomfort than a
routine venipuncture [23]. Abdominal and buttock adi-
pose tissue samples can be safely stored for up to 1.5 year
without changes in the FA component [23]. Abdominal
adipose tissue samples were taken from the left upper
quadrant of the abdominal area, and in close proximity to
the umbilicus. Buttock adipose tissue samples were taken
from the left upper outer quadrant of the gluteal area.
Both abdominal and buttock adipose tissue samples were
taken through the use of 10 ml vacutainer tubes. Prior to
aspiration, aspiration sites were sprayed with local anaes-
thetic (ethyl chloride).
Adipose tissue samples were stored at -80°C. Prior to
analysis, the samples were thawed and the fat was trans-
ferred to 10 ml screw-capped tubes using Pasteur pipettes
and several drops (~0.5 ml) of chloroform: methanol
(2:1, v/v). Methyl esters of the fat component FAs (FAME)
were prepared in the screw-capped vials according to the
method described by Metcalfe et al (1966) [24]. Briefly,
20–30 mg of fat sample were saponified with 1.0 ml
NaOH in methanol and the FAME were prepared with
14% boron trifluoride in methanol following extraction
with hexane after washing with saturated NaCl. The hex-
ane (upper layer) containing the FAME was transferred to
GC vials and stored at -20°C until analysis. The FAME
were separated on a 100 × 0.25 mm Id. SP-2560 fussed sil-
ica capillary column, coated with 0.25 μm of cyanopropyl
silicone provided by SUPELCO (Bellefonte, PA, USA –
SGE Australia), using a Shimadzu (Shimadzu Corpora-
tion Kyoto Japan) GC-17A/FID gas chromatograph
equipped with an AOC-20I auto injector. The Class-VP
chemstation software was used for identification and
quantification of the peaks.
Baseline separation of over 50 FAME peaks was accom-
plished by means of mixed FAME standards (Sigma). The
analytical conditions employed were as follows: 1 μl vol-
ume injected, helium carrier gas (1.1 ml/min), an injector
temperature of 250°C, FID 260°C, split ratio 1:4 to 1:20
(depending on the sample quantity), and oven tempera-
ture from 140°C to 245°C with a stepped temperature
program, within a total run time of 54 min.
The FAs extracted from adipose tissue lipids were C12:0,
C14:0, C14:1n-5t, C14:1n-7t, C14:1n-9t, C15:0, C16:0,
C16:1n-9t, C16:1n-7c, C16:1n-9c, C17:0, C18:0, sum of
all  trans  C18:1, C18:1n-9c, C18:1n-11cis, C18:1n-12c,
C18:1n-13c, C18:1n-14c, C18:2n-9t,12t, C18:2n-9c,12t,
C18:2-9c,12c, C20:0, C18:3n-6, C20:1, C18:3n-3, C18:2
conjugated, C20:2n-9, C20:2n-6, C20:3n-6, C20:4n-6,
C20:3n-3, C20:5n-3, C22:3n-3, C22:4, C22:5n-3 and
C22:6n-3. All identified peaks were included in the statis-
tical analyses.
In addition, the four fatty acid clusters SFA, MUFA, PUFA
and  trans  FAs, the ratio of n-6:n-3 FAs, the ratios
SFA:MUFA and SFA:PUFA and the sum of EPA and DHA
were considered.
Gastric mucosal tissue measures
Endoscopic pinch biopsy was used to obtain eight tissue
samples from the pyloric antrum of each patient. Where a
gastric ulcer was evident, the samples were collected from
sites that were at a distance from the lesion.
Gastric mucosal tissue was stored at -80°C. Prior to anal-
ysis, the samples were thawed and the pinch biopsy was
transferred to 10 ml screw-capped tubes using Pasteur
pipettes and several drops (~0.5 ml) of chloroform: meth-
anol (2:1, v/v). Methyl esters of the fat component FAs
were prepared in the screw-capped vials according to the
method described by Metcalfe et al (1966) [24]. Briefly,
20–30 mg of gastric tissue sample were saponified with
1.0 ml NaOH in methanol and the FAME were prepared
with 2 mL 14% boron trifluoride in methanol following
extraction with hexane after washing with 3.0 ml of satu-
rated NaCl. The hexane (upper layer) containing the
FAME was transferred to GC vials and stored at -20°C
until analysis. The FAME of the gastric tissue were released
from both triacyglycerols and phospholipids since the
total quantity of the gastric tissue collected from each
patient was relatively small. The FAME were separated on
a 100 × 0.25 mm Id. SP-2560 fussed silica capillary col-BMC Gastroenterology 2009, 9:9 http://www.biomedcentral.com/1471-230X/9/9
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umn, coated with a 0.25 μm of cyanopropyl silicone pro-
vided by SUPELCO, using a Shimadzu GC-17A gas
chromatograph equipped with an AOC-20I auto sampler
and a FID. The Class-VP chemstation software was used
for identification and quantification of the peaks.
The FAME extracted from some of the samples were also
separated on a second capillary column in order to com-
pare the results and decide on the most appropriate col-
umn to use. The column used was the BPX70 50 × 0.22
mm 0.25 U fusse silica column, coated with 0.2 μm of bis-
cyanoproplyl polysiloxane, using a Shimadzu (Shimadzu
Corporation Kyoto Japan) GC 2010GC gas chromato-
graph equipped with an AOC-20I auto sampler and an
FID. When using the second column, the GC Solution
software was used for peak identification and quantifica-
tion. As the first column (SP-2560) provided a clearer
analysis of the cis- and trans- isomers of C18:1 and C18:2,
it was used for all analyses.
Baseline separation of the FAME peaks was accomplished
by means of mixed FAME standards (Sigma). The analyti-
cal conditions employed were as follows: 1 μl volume
injected, helium carrier gas used (20 cm/sec) (hydrogen
for BPX70), injector temperature 250°C, FID temperature
250°C, split ratio 1:20 to 1:50 (depending on the sample
quantity), and oven temperature from 140°C to 240°C
(from 90°C to 230°C for BPX70) with a stepped temper-
ature program within a total run time 60 min.
The FAs extracted from the gastric mucosa lipids were
C12:0, C13:0, C14:0, C15:0, C16:0, C17:0, C18:0, C20:0,
C22:0, C14:1n-9c, C16:1n-9c, C18:1n-9c, C18:1n-11c,
C18:1n-12c, C18:1n-13c, C18:1n-14c, C20:1, C16:1n-5,
C16:2n-4, C16:4n-1, C16:3n-4, C18:2-9c,12c, C18:3n-3,
C18:3n-6, C18:2 conjugated, C20:3n-3, C20:3n-6,
C20:4n-3, C20:4n-6, C20:5n-3, C21:5n-3, C22:4n-3,
C22:5n-3, C22:6n-3, C22:5n-6, C16:1n-9t, C14:1n-5t,
C14:1n-7t, sum of all trans C18:1, C18:2n-9t,12t, C18:2n-
9c,12t and C18:2n-9t,12c. All identified peaks were
included in the statistical analyses.
In addition, as in the adipose tissue, the four fatty acid
clusters SFA, MUFA, PUFA and trans FAs, the ratio of n-
6:n-3 FAs, the ratios SFA:MUFA and SFA:PUFA and the
sum of EPA and DHA were considered.
Data analysis
The chi-squared test of independence was applied to test
for possible associations between categorical variables.
Pearson's correlation coefficient was calculated to assess
possible linear correlations between FAs from each of the
three sites. Average levels of FAs were compared between
the two gastric ulceration status groups using Student's t-
test for independent samples at each of the three sites. In
addition, analysis of covariance was undertaken to adjust
for the possible confounding effect of age. Results were
considered significant at the 5% level. The statistical pack-
age SPSS 15.0 was used throughout.
Results
Of the 52 outpatients who participated in the study, 16
(31%) were found to have gastric ulceration. Twenty
patients (39%) were CLO positive. CLO positivity was
found to be strongly associated to gastric ulceration status
(p = 0.003): eleven out of 16 patients with gastric ulcera-
tion were CLO positive (69%), whereas the number of
CLO positive patients without gastric ulceration was nine
out of 36 (25%). Age distribution also differed according
to ulceration status: patients suffering from gastric ulcera-
tion had an average age of 67 years (SD = 15.2) whereas
the mean age of patients without gastric ulceration was 58
years (SD = 17.4).
A positive linear correlation was found between the fatty
acid clusters at each of the two adipose tissue sites: SFA (r
= 0.73, p < 0.0001), MUFA (r = 0.81, p < 0.0001), PUFA
(r = 0.84, p < 0.0001), n-3 cluster (r = 0.54, p < 0.0001),
n-6 cluster (r = 0.83, p < 0.0001), trans (r = 0.612, p <
0.0001), MUFA:PUFA ratio (r = 0.86, p < 0.0001),
MUFA:SFA ratio (r = 0.74, p < 0.0001), n-3:n-6 ratio (r =
0.63, p < 0.0001) and the sum of EPA and DHA (r = 0.88,
p < 0.0001) using measurements from the 42 subjects
who had samples from both sites.
Weak evidence of a positive correlation was found
between adipose tissue and gastric mucosa for the n-6
cluster (buttock r = 0.37, p = 0.043, n = 30) and the trans
cluster (abdomen r = 0.41, p = 0.047, n = 23). No other
statistically significant correlations were detected between
adipose and gastric tissue.
Average fatty acid composition was not found to differ
between subjects with and without gastric ulceration in
the two adipose tissue sites. Differences in average fatty
acid composition in the gastric mucosa were, however,
detected. Details are provided in Table 1. In summary, sta-
tistically significant differences were found for the SFAs
C13:0 and C15:0 with higher average levels in patients
with gastric ulceration. Mean levels of the following
MUFAs were also found to differ to a statistically signifi-
cant extent between the two groups: C14:1n-9c, C16:1n-5,
C16:4n-1, C18:1n-12c and C20:1 with higher average lev-
els of C14:1n-9c and C20:1 and lower levels of C16:1n-5,
C16:4n-1 and C18:1n-12c in patients with gastric ulcera-
tion. The PUFAs that differed were the following: C16:2n-
4, C16:3n-4, C20:3n-3, C20:4n-6, C21:5n-3, C22:4n-3
and the trans C18:2n-9c,12t with higher average levels of
C16:2n-4 in ulcer positive patients and higher average lev-
els of C16:3n-4, C20:3n-3, C20:4n-6, C21:5n-3, C22:4n-3BMC Gastroenterology 2009, 9:9 http://www.biomedcentral.com/1471-230X/9/9
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Table 1: Average levels of fatty acids extracted from the gastric mucosa lipids according to the presence (N = 11) or absence (N = 19) 
of peptic ulceration.
Fatty acid Ulcer present
(N = 11)
No ulcer present
(N = 19)
95% Confidence interval. p-value p-value adjusted for age
Mean (SE) Mean (SE)
SFAa 30.12 (0.540) 28.31 (0.668) -0.179 to 3.806 0.073 0.069
MUFAb 27.17 (0.735) 25.87 (0.491) -0.442 to 3.052 0.137 0.156
PUFAc 39.19 (0.825) 41.01 (0.510) -3.701 to 0.052 0.056 0.090
n-3* 17.72 (1.407) 18.88 (0.550) -3.787 to 1.468 0.374 0.410
n-6** 18.01 (0.768) 18.07 (0.503) -1.869 to 1.740 0.942 0.856
n-6/n-3 1.09 (0.100) 0.98 (0.045) -0.080 to 0.313 0.237 0.205
MUFA/SFA 0.91 (0.034) 0.92 (0.020) -0.087 to 0.061 0.729 0.675
MUFA/PUFA 0.70 (0.028) 0.63 (0.019) 0.004 to 0.131 0.065 0.089
EPA† + DHA‡ 14.34 (1.306) 15.14 (0.550) -3.305 to 1.698 0.516 0.560
Total trans 0.94 (0.074) 0.98 (0.054) -0.220 to 0.150 0.702 0.700
Saturated fatty acids
C12:0 0.36 (0.046) 0.31 (0.039) -0.087 to 0.169 0.519 0.837
C13:0 0.39 (0.077) 0.17 (0.031) 0.081 to 0.371 0.003 0.005
C14:0 0.65 (0.071) 0.53 (0.040) -0.029 to 0.279 0.108 0.088
C15:0 1.92 (0.053) 1.56 (0.071) 0.158 to 0.576 0.001 0.002
C16:0 17.38 (0.344) 16.40 (0.390) -0.207 to 2.155 0.103 0.072
C17:0 0.36 (0.040) 0.31 (0.032) -0.058 to 0.152 0.371 0.481
C18:0 8.03 (0.292) 8.28 (0.364) -1.333 to 0.834 0.641 0.672
C20:0 0.23 (0.051) 0.16 (0.012) -0.020 to 0.148 0.134 0.190
C22:0 0.51 (0.131) 0.28 (0.055) -0.018 to 0.481 0.069 0.070
Monounsaturated fatty acids
C14:1n-9c 0.25 (0.028) 0.17 (0.007) 0.035 to 0.130 0.001 0.001
C16:1n-5 0.09 (0.019) 0.17 (0.019) -0.133 to -0.013 0.018 0.010
C16:1n-9c 0.55 (0.057) 0.55 (0.044) -0.153 to 0.142 0.943 0.867
C16 :4n-1 0.60 (0.056) 0.78 (0.046) -0.332 to -0.027 0.022 0.020
C18:1n-9c 22.38 (0.608) 21.19 (0.485) -0.428 to 2.799 0.144 0.169
C18:1n-11c 2.09 (0.042) 2.00 (0.057) -0.073 to 0.263 0.259 0.273
C18:1n-12c 0.09 (0.009) 0.13 (0.009) -0.066 to -0.011 0.006 0.012
C18:1n-13c 0.04 (0.006) 0.02 (0.006) -0.001 to 0.035 0.059 0.035
C18:1n-14c 0.14 (0.018) 0.13 (0.009) -0.032 to 0.041 0.814 0.615
C20:1 0.20 (0.030) 0.11 (0.009) 0.037 to 0.140 0.001 0.001
Polyunsaturated fatty acids
C16:2n-4 0.55 (0.057) 0.33 (0.031) 0.973 to 0.339 0.001 0.001
C16:3n-4 1.13 (0.079) 1.45 (0.089) -0.592 to -0.053 0.021 0.014
C18:2-9c,12c 16.97 (0.864) 16.57 (0.514) -1.521 to 2.328 0.671 0.497
C18:3n-3 0.34 (0.056) 0.47 (0.067) -0.331 to 0.072 0.200 0.167
C18:3n-6 0.14 (0.018) 0.15 (0.023) -0.077 to 0.058 0.778 0.700
C18:2 conjugated 0.10 (0.008) 0.08 (0.005) -0.002 to 0.032 0.095 0.061
C20:3n-3 0.04 (0.01) 0.34 (0.07) -0.493 to -0.092 0.006 0.004
C20:3n-6 0.05 (0.008) 0.04 (0.010) -0.014 to 0.044 0.307 0.241
C20:4n-3 2.20 (0.114) 1.91 (0.118) -0.076 to 0.655 0.116 0.110
C20:4n-6 0.11 (0.018) 0.38 (0.084) -0.492 to -0.035 0.025 0.018
C20:5n-3 11.58 (1.119) 12.53 (0.440) -3.043 to 1.147 0.362 0.433
C21:5n-3 0.13 (0.014) 0.23 (0.015) -0.148 to -0.057 <0.0001 <0.0001
C22:4n-3 0.15 (0.030) 0.22 (0.017) -0.134 to -0.001 0.045 0.047
C22:5n-3 0.67 (0.136) 0.79 (0.036) -0.350 to 0.109 0.293 0.373
C22:6n-3 2.75 (0.222) 2.61 (0.223) -0.549 to 0.838 0.673 0.792
C22:5n-6 0.73 (0.145) 0.94 (0.053) -0.474 to 0.055 0.117 0.139
trans
C14:1n-5t 0.09 (0.017) 0.11 (0.017) -0.080 to 0.027 0.318 0.199
C14:1n-7t 0.33 (0.046) 0.28 (0.032) -0.060 to 0.163 0.351 0.514BMC Gastroenterology 2009, 9:9 http://www.biomedcentral.com/1471-230X/9/9
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and C18:2n-9c,12t in ulcer negative patients. Details are
provided in Table 1.
In subjects who were not found to have a gastric ulcer,
abdominal tissue fatty acid composition was found to dif-
fer according to CLO status, there being higher levels of
the SFAs C12:0 and C20:0 in abdominal tissue in CLO
positive patients. In contrast, the average levels of C20:4n-
6, C20:3n-3, C20:5n-3, C22:4, C22:5n-3 and C22:6n-3
were found to be significantly lower in CLO positive
patients. Details are provided in Table 2.
Regarding the fatty acid composition of the buttock tissue,
there seems to be a possible relationship with the CLO sta-
tus in subjects without gastric ulcer. Levels of the SFAs
C20:0 and C12:0 and the MUFA C20:1 were higher in
CLO positive patients, whereas the levels of C16:1n-7c,
C20:3n-6, C20:4n-6, C22:5n-3 and C22:6n-3 were lower.
Details are provided in Table 2.
C16:1n-9t 0.18 (0.027) 0.21 (0.023) -0.107 to 0.041 0.372 0.374
C18:1n-t 1 0.23 (0.012) 0.32 (0.038) -0.190 to 0.019 0.108 0.162
C18:2n-9t,12t 0.12 (0.029) 0.06 (0.021) -0.014 to 0.130 0.111 0.047
C18:2n-9c,12t 0.17 (0.039) 0.42 (0.068) -0.437 to -0.050 0.015 0.009
C18:2n-9t,12c 0.12 (0.009) 0.27 (0.068) -0.333 to 0.037 0.114 0.063
a SFA = sum of saturated fatty acids
b MUFA = sum of monounsaturated fatty acids
c PUFA = sum of polyunsaturated fatty acids
* sum of n-3 fatty acids
** sum of n-6 fatty acids
†Eicosapentaenoic acid C20:5n-3 (EPA)
‡Docosahexaenoic acid C22:6n-3 (DHA)
1 All trans C18:1 (C18:1n-6t, C18:1n-7t, C18:1n-8t and C18:1n-9t)
Table 1: Average levels of fatty acids extracted from the gastric mucosa lipids according to the presence (N = 11) or absence (N = 19) 
of peptic ulceration. (Continued)
Table 2: Average levels of fatty acids extracted from adipose tissue lipids in patients without gastric ulcer according to CLO status. (N 
= 30)1
Abdominal tissue
Fatty acid CLO + (N = 7) CLO - (N = 23) 95% Confidence interval. p-value
Mean (SE) Mean (SE)
n-3* 1.02 (0.065) 1.27 (0.054) -0.469 to -0.038 0.023
C12:0 0.34 (0.091) 0.19 (0.020) 0.026 to 0.274 0.019
C20:0 0.16 (0.016) 0.12 (0.009) 0.001 to 0.075 0.044
C20:4n-6 0.32 (0.040) 0.44 (0.026) -0.224 to -0.009 0.035
C20:3n-3 0.03 (0.005) 0.05 (0.004) -0.035 to -0.001 0.037
C20:5n-3 0.02 (0.002) 0.04 (0.003) -0.026 to -0.006 0.002
C22:4 0.03 (0.002) 0.04 (0.003) -0.023 to -0.003 0.012
C22:5n-3 0.11 (0.011) 0.18 (0.011) -0.107 to -0.023 0.004
C22:6n-3 0.10 (0.008) 0.19 (0.015) -0.142 to -0.031 0.003
Buttock tissue
Fatty acid CLO + (N = 7) CLO - (N = 23) 95% Confidence interval. p-value
Mean (SE) Mean (SE)
C12:0 0.26 (0.061) 0.16 (0.017) 0.004 to 0.186 0.042
C20:0 0.13 (0.014) 0.09 (0.005) 0.017 to 0.065 0.001
C16:1n-7c 0.79 (0.048) 0.93 (0.034) -0.268 to -0.003 0.046
C20:1 0.44 (0.034) 0.38 (0.013) 0.003 to 0.123 0.039
C20:3n-6 0.20 (0.029) 0.27 (0.016) -0.138 to -0.007 0.030
C20:4n-6 0.34 (0.051) 0.45 (0.026) -0.217 to 0.001 0.050
C22:5n-3 0.13 (0.012) 0.18 (0.011) -0.090 to -0.011 0.015
C22:6n-3 0.12 (0.013) 0.18 (0.012) -0.112 to -0.021 0.006
* sum of n-3 fatty acids
1 Only comparisons that are statistically significant at the 5% level are presented in the above Table (p < 0.05)BMC Gastroenterology 2009, 9:9 http://www.biomedcentral.com/1471-230X/9/9
Page 7 of 9
(page number not for citation purposes)
Discussion
In the present study, no notable differences in adipose
fatty acid composition were found between subjects with
and without gastric ulceration. These findings are in agree-
ment with those of a study that examined the possible pre-
ventative role of linoleic (C18:2n-6) fatty acid in gastric
ulceration. The authors came to the conclusion that there
was no significant difference in the adipose tissue content
of linoleic acid between patients with gastric ulcer disease
and matched control subjects [25]. Our findings are, how-
ever, in contrast to the results of Grant et al (1990) and
Prichard et al (1988) who presented a possible preventing
role of dietary intake of linoleic fat acid and olive oil in
gastric ulceration [26,27].
In our study, ulcer-negative subjects were found to differ
in adipose tissue fatty acid composition according to CLO
status, there being higher levels of C20:4n-6, C20:3n-3,
C20:5n-3 (EPA), C22:4, C22:5n-3 and C22:6n-3 (DHA) in
abdominal samples and C16:1n-7cis, C20:3n-6, C20:4n-6,
C22:5n-3 and C22:6n-3 in buttock samples in CLO nega-
tive patients.
It is possible that the consumption of PUFAs inhibits the
growth of H. pylori and the colonization of the gastric
mucosa, a hypothesis that is in agreement with previous
studies showing that ingested dietary PUFAs inhibit the
growth of H. pylori in vitro [5,28]. These studies suggest
that the inhibitory effect of PUFAs to H. pylori is due: (a)
to the disruption of the bacterial outer lipid membrane
which leads to cell lysis and (b) to the polyunsaturated
induced increased permeability of the bacterial cell mem-
branes which leads to dissipated concentration gradients
between the organism and its environment, such as those
for hydrogen ions with fatal outcomes for H. pylori [5].
It is also possible that the higher levels of some PUFAs,
especially those of the n-3 group, in CLO negative patients
reflect the role of FAs to the modulation of immune
responses to H. pylori. Adipose tissue functions are, in fact,
crucial in protective immunity against noxious agents
such as H pylori. Mueller et al (2003) have concluded that
a number of genes specifically expressed in fat cells/adi-
pocytes, tightly correlate with protection from H. pylori.
Among these are genes for three adipocyte-specific
cytokines, the so-called "adipokines," adipsin, resistin,
and adiponectin [8]. It has also been suggested that the
secreted adipokines are likely mediators of crosstalk with
lymphocytes. This paracrine relationship between adipose
and lymphoid tissues possibly explains the link between
the production and secretion of adipokines and a protec-
tive response against H. pylori [8]. It is possible that
secreted adipocyte factors stimulate the effector functions
of resident T cell populations [8]. This hypothesis is sup-
ported by numerous studies demonstrating an essential
role of CD4+ T cells in the protection against H. pylori [29-
31].
Findings from dietary intervention studies lead, however,
to conclusion that PUFAs, when orally ingested as dietary
supplements, do not inhibit either the colonization of the
mucosa by H. pylori or the inflammatory changes charac-
teristic of H. pylori gastritis [28]. It may be that the absorp-
tion and distribution of PUFAs derived from capsules
differ from those naturally present in the diet. Further
research could investigate whether the long term supply of
digested PUFA foods, as estimated by the adipose tissue
fatty acid composition, is of greater effectiveness against
H. pylori infection than the short term per os supply of
high doses of PUFA.
To the best of our knowledge, this is the first literature
report of a possible association between fatty acid compo-
sition of the gastric mucosa and the presence of gastric
ulceration. It was found that the MUFAs C18:1n-12c,
C16:1n-5 and C16:4n-1 and the PUFAs C16:3n-4, C20:3n-
3, C20:4n-6, C21:5n-3, C22:4n-3 and C18:2n-9c,12t were
present at somewhat higher levels in the gastric mucosa of
ulcer-negative patients, leading to the hypothesis that
some PUFAs may possibly play a possible preventive role
in gastric ulceration. Additionally, there were significantly
higher proportions of C13:0, C15:0, C14:1n-9c and C20:1
in the gastric mucosa of patients with gastric ulcer disease,
also indicating a possible protective role for some FAs ver-
sus others in gastric ulceration.
Arachidonic acid (C20:4n-6) is incorporated in mem-
brane phospholipids. Surface active phospholipids, espe-
cially phosphatidylcholine, play an important role in the
first line of defense of the stomach, most likely because of
their hydrophobic properties. Both membrane hydropho-
bicity and permeability are known to be influenced by the
saturation level and chain length of FAs that composes the
surface active phospholipids [20].
In addition, arachidonic acid is a precursor fatty acid in
the prostaglandin synthesis pathway. PGs of the E, A and
I series have been shown to suppress basal and stimulated
gastric acid secretion in rats and normal human subjects
[32]. Furthermore, it has been demonstrated that PGs of
the E type are capable of preventive formation of gastric
ulcers in rats induced by a wide variety of experimental
techniques [33]. Tarnawski et al (1987) also showed a sig-
nificant cytoprotective effect of oral administration of
linoleic acid on ethanol-induced gastric injury, an effect
significantly reduced by pre-treatment with oral
indomethacin, a known inhibitor of prostaglandin syn-
thetase [34].BMC Gastroenterology 2009, 9:9 http://www.biomedcentral.com/1471-230X/9/9
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Both the design of our study and the results themselves,
however, cannot lead to the conclusion of a definitive
relation between fatty acid composition and gastric ulcer-
ation status. In addition, it is known that when multiple
comparisons are undertaken, there is an effective increase
in the significance level. Adjusting for multiple compari-
sons using the Bonferroni correction (adjusted alpha =
0.001), results in only C14:1n-9 c, C20:1, C16:2n-4 and
C21:5n-3 remaining statistically significant at the unad-
justed 5% level (Table 1). None of these fatty acids con-
tributed more than 1% on average to the total fatty acid
content. The biological relevance of the statistically signif-
icant results is not clear. The role that CLO status may play
in the relation between fatty acid composition and the
presence of gastric ulceration could not be investigated (or
accounted for in the statistical analysis) as 18 of the 19
subjects without a gastric ulcer from whom a gastric
mucosal sample was taken, were CLO negative. Since it is
known that H. pylori infection alters not only the gastric
mucosal phosphatidylcholine content, but also its fatty
acid composition, which may consequently cause the gas-
tric mucosal barrier to weaken, further investigation is
needed in order to clarify the relation of the fatty acid
composition of the gastric mucosa to H. pylori coloniza-
tion.
Conclusion
Certain MUFAs and PUFAs of the gastric mucosa appear to
be present in somewhat higher proportions in ulcer nega-
tive patients. These findings seem to suggest a possible
protective role of the gastric mucosa FAs in gastric ulcera-
tion, although statistically significant differences were
found only in certain minor FAs i.e. FAs contributing only
a very small fraction of the total fatty acid contents. The
higher average levels of EPA and DHA in abdominal and
buttock adipose tissue in CLO negative, ulcer negative
patients, may also suggest that dietary FAs could inhibit
H. pylori growth. Further studies are required to ascertain
whether such FAs do, in fact, play a role in the prevention
of gastric ulceration.
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